Vepdegestrant
Vepdegestrant - 5mg is backordered and will ship as soon as it is back in stock.
Couldn't load pickup availability
Vepdegestrant (ARV-471) is a PROTAC protein degrader for breast cancer. Vepdegestrant facilitates the interactions between estrogen receptor alpha and an intracellular E3 ligase complex and leads to degradation of ER in ER-positive breast cancer cell lines.
| Product Name | Vepdegestrant |
| Synonyms | ARV-471 |
| CAS Number | 2229711-68-4 |
| Related CAS | |
| Molecular Formula | C45H49N5O4 |
| Molecular Weight | 723.918 |
| SMILES | OC1=CC=C2[C@H]([C@H](CCC2=C1)C1=CC=CC=C1)C1=CC=C(C=C1)N1CCC(CN2CCN(CC2)C2=CC3=C(C=C2)C(=O)N(C3)[C@H]2CCC(=O)NC2=O)CC1 |
| Purity (HPLC) | >= 95% |
| Physical Appearance | White solid |
| Solubility | DMSO, DMF |
| Shipping Conditions | Room Temperature |
| Storage Conditions | Refrigerated |
| Shelf Life | 12 months after the date of delivery |
| Regulatory Statement | For Research Use Only |
References
Flanagan JJ, Qian Y, Gough SM, Andreoli M, Bookbinder M, Cadelina G, Bradley J, Rousseau E, Willard R, Pizzano J, Crews CM, Crew AP, Taylor I, Houston J. ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-04-18. https://doi.org/10.1158/1538-7445.SABCS18-P5-04-18
Documents
Datasheet COA MSDS
Citations
If you know of a paper that uses this product from Tenova Pharma, please let us know.
